The U.S. Food and Drug Administration (FDA) has clearly indicated that extension of the current “partial shutdown” of the government will, in the not too distant future, start to delay approvals of new drugs and diagnostics and new indications for currently marketed drugs. … READ MORE …
Filed under: Uncategorized | Tagged: approval, diagnostic, drug | Leave a comment »
For many years now, here in the USA, access to FDA-approved drugs for the treatment of cancer and other severe forms of disorder have been guaranteed under Medicare. … READ MORE …
Filed under: Management, Treatment | Tagged: access, advocacy, drug, FDA-approved, therapy | 1 Comment »
A report yesterday on on the MedPage Today web site quotes Scott Gottlieb, MD, the Commissioner of the U.S. Food & Drug Administration (FDA) on the importance of “Listening to patients” and on how patients’ perspectives can inform drug development, drug review, and physicians’ prescribing habits. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: development, drug, opinion, patient, regulation | 1 Comment »
The issue as to whether the new, so-called “right-to-try” legislation is a good idea or not is contentious and your sitemaster has no interest in getting into that discussion. What is a fact is that it has now been signed into law. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: "right to try", access, bill, drug, investigational, law | 2 Comments »
According to a recently published article in The Prostate, researchers at the University of Minnesota have developed a new type of drug that they believe may have high therapeutic potential in the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development | Tagged: CRPC, development, drug, Minnelide, triptolide | 5 Comments »
So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: analysis, development, drug, information, new, ongoing | 4 Comments »
Readers with an interest in how we got to today’s clinical trials processes for evaluating new drugs for the treatment of prostate cancer and other diseases might be surprised by what’s in an article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, marketing, regulation, trials | 2 Comments »
For readers who are interested in the processes and the speed with which potential new cancer drugs can be brought to market here in the USA (and other places around the world too), there in an important article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: development, drug, effectiveness, new, safety, speed | Leave a comment »
Yet another set of researchers have found yet another possible new drug that seems to have significant activity in management of prostate cancer — in mice! Whether it will have activity in men is a whole other question. … READ MORE …
Filed under: Drugs in development, Management | Tagged: active, drug, investigational, IPA-3, mice | 4 Comments »
Many readers of this blog will be aware of the development of immunotherapies like sipuleucel-T (Provenge), CAR-T for the treatment of leukemias, and checkpoint inhibitors in the treatment of some forms of solid tumor (lung cancers, melanoma). … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, immunotherapy, neoantigen | Leave a comment »
In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: access, cost, drug, life, price, survival, value | 5 Comments »
As many of our readers will be well aware, The “New” Prostate Cancer InfoLink has long argued that, if the biopharmaceutical industry doesn’t take serious steps to manage the problems of increasing prices that come with no real commensurate value, then someone else will take those steps for them. … READ MORE …
Filed under: Uncategorized | Tagged: controls, drug, prices | 8 Comments »
According to an announcement this morning from The Mayo Clinic, a group of 118 leading cancer experts has drafted proposals for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advocacy, cost, drug, price | 5 Comments »
Yesterday the American Society of Clinical Oncology (ASCO) issued the initial draft of “a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities, and costs.” ASCO is interested in getting feedback from its members and from the patient community too. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: benefit, cost, drug, Treatment, value | 5 Comments »
As most of the readers of these blog posts will be all too well aware, the costs of prescriptions drugs for the treatment of prostate cancer have been rising significantly in recent years, … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: assistance, copay, cost, drug, patient | 6 Comments »
